Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Liver‐Targeting Acetyl‐CoA Carboxylase Inhibitor (PF‐05221304): A Three‐Part Randomized Phase 1 Study

por Bergman, Arthur, Carvajal‐Gonzalez, Santos, Tarabar, Sanela, Saxena, Aditi R., Esler, William P., Amin, Neeta B.
Publicado 2020

Pharmacological Inhibition of CETP (Cholesteryl Ester Transfer Protein) Increases HDL (High-Density Lipoprotein) That Contains ApoC3 and Other HDL Subspecies Associated With Higher...

por Furtado, Jeremy D., Ruotolo, Giacomo, Nicholls, Stephen J., Dullea, Robert, Carvajal-Gonzalez, Santos, Sacks, Frank M.
Publicado 2021

Acetyl-CoA Carboxylase Inhibition Improves Multiple Dimensions of NASH Pathogenesis in Model Systems

por Ross, Trenton T., Crowley, Collin, Kelly, Kenneth L., Rinaldi, Anthony, Beebe, David A., Lech, Matthew P., Martinez, Robert V., Carvajal-Gonzalez, Santos, Boucher, Magalie, Hirenallur-Shanthappa, Dinesh, Morin, Jeffrey, Opsahl, Alan C., Vargas, Sarah R., Bence, Kendra K., Pfefferkorn, Jeffrey A., Esler, William P.
Publicado 2020

Decreasing the Rate of Metabolic Ketone Reduction in the Discovery of a Clinical Acetyl-CoA Carboxylase Inhibitor for the Treatment of Diabetes

por Griffith, David A., Kung, Daniel W., Esler, William P., Amor, Paul A., Bagley, Scott W., Beysen, Carine, Carvajal-Gonzalez, Santos, Doran, Shawn D., Limberakis, Chris, Mathiowetz, Alan M., McPherson, Kirk, Price, David A., Ravussin, Eric, Sonnenberg, Gabriele E., Southers, James A., Sweet, Laurel J., Turner, Scott M., Vajdos, Felix F.
Publicado 2014